{
    "clinical_study": {
        "@rank": "42032", 
        "arm_group": [
            {
                "arm_group_label": "Comp01", 
                "arm_group_type": "Active Comparator", 
                "description": "applied twice a day for 15 days"
            }, 
            {
                "arm_group_label": "DFD06 Cream", 
                "arm_group_type": "Experimental", 
                "description": "applied twice a day for 15 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the potential of DFD06 cream to suppress the HPA\n      (hypothalamic-pituitary-adrenal) axis as compared to Comp01 cream when applied twice daily\n      for 15 days."
        }, 
        "brief_title": "DFD06 Cream vs Comp01 Cream HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects must present with a clinical diagnosis of stable (at least 3 months) plaque\n        psoriasis.\n\n        Subjects with psoriasis involving 20 to 50% BSA, not including the face, scalp, groin,\n        axillae and other intertriginous areas.\n\n        Subjects must have an IGA grade of at least 3 (moderate) at the Baseline Visit Subjects\n        whose results from the screening ACTH stimulation test are considered normal (cortisol\n        level >18 ug/dL at 30 minutes post stimulation) and show no other signs of abnormal HPA\n        function or adrenal response\n\n        Exclusion Criteria:\n\n        Current diagnosis of unstable forms of psoriasis including guttate, erythrodemic,\n        exfoliative or pustular psoriasis.\n\n        History of organ transplant requiring immunosuppression, HIV, or other immunocompromised\n        state.\n\n        Have received treatment for any type of cancer within 5 years of the Baseline Visit except\n        skin cancer and cervical cancer (in situ) are allowed if at least 1 year before the\n        Baseline Visit.\n\n        Use within 60 days prior to the baseline Visit of: 1) immunosuppressive drugs (e.g.,\n        tacrolimus, pimecrolimus), or 2) systemic antipsoriatic treatment (e.g., methotrexate,\n        cyclosporine, hydroxyurea) Use within 30 days prior to the Baseline Visit of: 1) topical\n        antipsoriatic drugs (salicylic acid, anthralin, coal tar, calcipotriene), 2) PUVA therapy,\n        3) systemic anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine,\n        6-thioguanine), or 4) UVB therapy.\n\n        Use within 30 days prior to the Screening Visit of any product containing corticosteroids.\n        Inhaled, intraocular, intranasal, etc. steroids are not allowed.\n\n        Subjects who have an abnormal sleep schedule or work at night. Subjects with a known\n        history of acute adrenal crisis, Addison's disease or decreased adrenal output, low\n        pituitary function or pituitary tumors.\n\n        Subjects who have a history of an adverse reaction to cosyntropin injection or similar\n        test reagents.\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02131324", 
            "org_study_id": "DFD06-CD-007"
        }, 
        "intervention": [
            {
                "arm_group_label": "DFD06 Cream", 
                "intervention_name": "DFD06 Cream", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Comp01", 
                "intervention_name": "Comp01", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Psoriasis", 
        "lastchanged_date": "May 2, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Allan M Soo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Mesa", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85202"
                    }, 
                    "name": "Agave Clinical Research, LLC"
                }, 
                "investigator": {
                    "last_name": "Allan M Soo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Javier Alonso-Llamazares, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33144"
                    }, 
                    "name": "International Dermatology Research, Inc."
                }, 
                "investigator": {
                    "last_name": "Javier Alonso-Llamazares, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "antonio.jimenez@fxmresearch.com", 
                    "last_name": "Antonio Jimenez", 
                    "phone": "954-430-1097"
                }, 
                "contact_backup": {
                    "email": "francisco.moncada@fxmresearch.com", 
                    "last_name": "Francisco Moncada", 
                    "phone": "954-430-1097"
                }, 
                "facility": {
                    "address": {
                        "city": "Miramar", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33027"
                    }, 
                    "name": "FXM Research Miramar"
                }, 
                "investigator": {
                    "last_name": "Francisco Flores, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "huekluong@gmail.com", 
                    "last_name": "Hue K. Luong", 
                    "phone": "727-541-4431"
                }, 
                "contact_backup": {
                    "email": "schaundy@gmail.com", 
                    "last_name": "Shannon Chaundy", 
                    "phone": "727-541-4431"
                }, 
                "facility": {
                    "address": {
                        "city": "Pinellas Park", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33781"
                    }, 
                    "name": "Belleair Research"
                }, 
                "investigator": {
                    "last_name": "Gary Lee Heller, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John M Humeniuk, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Greer", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29650"
                    }, 
                    "name": "Radiant Research, Inc."
                }, 
                "investigator": {
                    "last_name": "John M Humeniuk, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Parallel Group, Open Label, to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD06 Cream Versus Comp01 Cream in Subjects With Moderate to Severe Plaque Psoriasis", 
        "overall_contact": {
            "email": "cfritz@promiuspharma.com", 
            "last_name": "Carmela Fritz, MS"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of subjects with HPA axis suppression.", 
            "safety_issue": "Yes", 
            "time_frame": "Day 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02131324"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Promius Pharma, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Promius Pharma, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}